Replay available

Nanologica AB (publ) (NICA) Q2 2025 Earnings Call

Nanologica AB (publ) (STO: NICA) Q2 2025 earnings conference call, held 2025-07-10. Replay captured from the company's public earnings webcast.

Thu, July 10, 2025 at 12:00 AMendedReplay
Nanologica AB (publ) (NICA) Q2 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Andreas Bhagwani

CEO of Nanologica

Replay transcript excerpt

Welcome to Redeye and today's interview with Nanologica and CEO Andreas Bhagwani, who is with us in Lina, down in India. Welcome, Andreas. Thank you. You released a report here just recently. Can you give a little more color to the report? What are the most important parts? I would say that the most important thing is that we have new customers coming in. We have not reached any milestone yet when it comes to production, it remains to come. And then it is interesting to just read the cash position. We had a lot of revenue in Q1 and when they come in, then the cash is largely neutral because that type of revenue is what we need to go around. So I would say that good customer activity, not yet finished with production, completely in the cash position. We can go directly into production. You mentioned in Q1 that you were waiting for essentially improved production after Q2. You also comment on this in the report, but what is the status right now? The status is that the installation work on the new equipment that we have carried out since the end of last year is now complete. Within a week we will start the first batch with the new equipment and then we will run a couple of batches before we feel that it is stable. We have taken another production step in this equipment, so we are not really worried about that. But before you hear me say that the production is rolling steadily, we want to have run a few batches. But the idea is that the first batch should be run as soon as possible. Will there be further adjustments under H2 or further improvements under H2? And can you mention anything about your insight into the delivery times at the moment? That's a really good question. I would say that with the facet in hand, I should be a bit defensive, because it's often things th...

More from Nanologica Ab